PPD wins 7-year HIV research contract

The pact will see PPD offer up research services for the fight against the infectious disease.

Major CRO player Pharmaceutical Product Development (PPD) has won a lucrative seven-year government contract in infectious disease.

The pact, financials details of which were not revealed, falls under the Clinical Research Support Services program of the Division of AIDS, National Institute of Allergy and Infectious Diseases, which is part of the National Institutes of Health.

Under the contract, PPD said it will “provide a broad range of clinical and other related research support services for the NIAID/DAIDS-supported clinical research portfolio and other infectious diseases relevant to HIV-infected and at-risk populations.”


Overcoming Risk in Oncology Drug Development

Oncology drug development is full of potential obstacles and risks, and you must carefully plan each step. Download this whitepaper for tips on finding the fast track. Premier Research. Built for Biotech.

“We are pleased to help NIAID develop and maintain a strong clinical infrastructure to meet the needs of DAIDS’ scientific agenda,” said William Sharbaugh, COO of the company.

RELATED: PPD to run first-in-human trial of Treos’ lead cancer vaccine

This latest agreement complements a long-standing collaboration between PPD and NIAID that, in March, was boosted to the middle of next decade, with PPD working on a "broad scope of research" in HIV.

Suggested Articles

Data firm Syapse has begun working with the FDA to help bring real-world evidence to bear on the agency’s decisions to approve cancer drugs.

The People-Centered Research Foundation tapped Datavant to de-identify real-world data across its national clinical research network.

Boehringer Ingelheim and MD Anderson Cancer Center have joined forces to create a “virtual” R&D hub so the pair can work on cancer drugs.